By Justin Petrone

GenMark Diagnostics this week reported revenue growth of 162 percent for its first quarter since going public in the US.

The company, which was based in London and known as Osmetech before going public in the US at the end of May, also announced that it is seeking a new CEO. Jon Faiz Kayyem, who previously served in that role, is now chief scientific officer. Christopher Gleeson, chairman of the firm, will serve as CEO on an interim basis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.